News
The Targeted Pulse: Trial Breakthroughs and FDA Decisions | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2+ hour, 56+ min ago (225+ words) Discover the latest breakthroughs in oncology, including FDA approvals, innovative treatments, and promising trial results shaping cancer care today. Tafasitamab Plus R-CHOP Improves PFS in First-Line DLBCL: Phase 3 Results FDA Grants Breakthrough Status to Sevabertinib in 1L HER2+ NSCLC The FDA has…...
Virtual Care Improves Mental Health in Patients With Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1+ day, 10+ hour ago (204+ words) Statistics emerge from a study on supportive care for oncology patients. Depression scores plummeted by over 6 points on the PHQ-9 scale, and anxiety symptoms showed a marked decrease of nearly 5 points on the GAD-7 tool, all within 5 months. Furthermore, the…...
FDA Fast-Tracks PARG Inhibitor for mBRCA Platinum-Resistant Ovarian Cancer
3+ day, 17+ hour ago (162+ words) ETX-19477 is a potent, selective inhibitor of poly(ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA damage response.3,4 Upon PARG inhibition, the agent is intended to inhibit cancer cell proliferation and induce selective apoptosis in tumors…...
Measuring the Impact of Virtual Collaborative Mental Health Care in Breast Cancer
3+ day, 18+ hour ago (128+ words) Researchers explore the impact of virtual collaborative care on mental health and quality of life for breast cancer patients, revealing significant improvements. In part 2 of the interview, Nina Balanchivadze, MD, Sarah Cannon Research Institute at Virginia Oncology Associates, and Kyle…...
FDA Pushes Z-Endoxifen Toward Next Step in Breast Cancer Treatment
3+ day, 20+ hour ago (433+ words) Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies. The FDA has issued a "Study May Proceed" letter for the study of patients with metastatic breast cancer being…...
CAR T in Heme Malignancies: Patient Outcomes Inform Care Needs | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
4+ day, 19+ hour ago (495+ words) A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges. A key highlight from the study, which captured survey responses from nearly 400 patients, was…...
Integrating Behavioral Health into Oncology: A Collaborative Approach
4+ day, 20+ hour ago (222+ words) Experts explore a virtual collaborative care model to enhance mental health support for breast cancer patients, aiming to improve treatment adherence and outcomes. In an interview with Targeted Oncology, Nina Balanchivadze, MD, Sarah Cannon Research Institute at Virginia Oncology Associates,…...
Patient Case #1: Newly Diagnosed Stage 3A NSCLC
4+ day, 21+ hour ago (158+ words) Patient Case #1: Newly Diagnosed Stage 3A NSCLC'Targeted Oncology This case explores optimal management of early-stage non'small cell lung cancer (NSCLC) requiring integrating imaging, laboratory findings, and molecular profiling to guide treatment decisions Key considerations include evaluating imaging and lab results for…...
NDA for Rusfertide Submitted to FDA for Polycythemia Vera
5+ day, 19+ hour ago (498+ words) A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes. The basis for NDA submission largely stems from the multi-part phase 3 VERIFY study (NCT05210790) of patients with PV, which met the first…...
Molecular Testing and Identifying Appropriate Patients for Lenvatinib Plus Pembrolizumab in Endometrial Cancer
6+ day, 21+ hour ago (121+ words) Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study results have shown regarding molecular testing and optimal use of lenvatinib plus pembrolizumab…...